INNOVATIONS in pharmacy
https://pubs.lib.umn.edu/index.php/innovations
<p style="caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration: none;"><em>Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy</em><br />A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, and review articles that focus on the leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. <em>INNOVATIONS in pharmacy</em> is an academic, peer reviewed, open-access journal. </p> <p style="caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration: none;">Sponsored by <a href="https://www.pharmacy.umn.edu/">U of MN College of Pharmacy</a></p>University of Minnesota Libraries Publishingen-USINNOVATIONS in pharmacy2155-0417<p>Copyright of content published in <em>INNOVATIONS in pharmacy</em> belongs to the author(s).</p>Implementation and evaluation of a learner-driven leadership initiative for pharmacy students and pharmacy residents.
https://pubs.lib.umn.edu/index.php/innovations/article/view/5767
<p>Introduction: Leadership training is a crucial component of the pharmacy education curriculum. ACPE standards 4 & 9 emphasize and encourage the use of different leadership initiatives while universities employ different tactics with varying levels of success. Leadership theory debates if leadership can be learned or if it is a natural born skill. This article explores learned leadership and describes a small study deployed to different levels of pharmacy learners to foster leadership confidence and self-awareness.</p> <p>Educational Context and Methods: Second- and third-year didactic students in a leadership elective, fourth-year APPE students on an ambulatory care rotation, and PGY1 pharmacy residents were included in this initiative. Each cohort facilitated a leadership book club discussion and completed professional development activities over the course of their experience. Learners’ perspectives on leadership were surveyed utilizing a pre-post survey study, administered prior to beginning the initiative and after completing the initiative.</p> <p>Findings and Discussion: Results demonstrated learners’ perceived confidence and self-awareness in their leadership skills increased from pre-survey to post-survey. Evaluation of qualitative responses exhibited that participants found value in adding more leadership development to their pharmacy training. Most participants noted leadership book discussion facilitation as the most valuable part of the initiative and posited they would utilize skills gained through these discussions nearly every day in their careers. Results suggest PGY1’s showed the most significant increase in their scores from pre- to post-study, while didactic students showed the least significant increase.</p> <p>Implications: Our findings suggest learner-driven leadership initiatives, specifically learner-facilitated book club discussions, are beneficial to incorporate into both didactic and experiential coursework. Implementation of these discussions could be applied in many aspects of the curriculum with minimal resources and a reasonable expectation of perceived benefit to student leadership development.</p>Molly CorderJason IschRyan Ades
Copyright (c) 2024 Molly M. Corder, Jason Isch, Ryan S. Ades
https://creativecommons.org/licenses/by-nc/4.0
2024-03-182024-03-1815110.24926/iip.v15i1.5767Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer’s Disease
https://pubs.lib.umn.edu/index.php/innovations/article/view/5787
<p><span class="TextRun SCXW7667757 BCX9" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW7667757 BCX9">T</span><span class="NormalTextRun SCXW7667757 BCX9">he</span><span class="NormalTextRun SCXW7667757 BCX9"> Food and Drug Administration granted </span><span class="NormalTextRun SCXW7667757 BCX9">traditional </span><span class="NormalTextRun SCXW7667757 BCX9">approval of lecanemab for the treatment of Alzheimer’s disease (AD). Lecanemab is a humanized anti-amyloid monoclonal antibody directed towards Aβ protofibrils. </span><span class="NormalTextRun SCXW7667757 BCX9">Lecanemab is the only drug that targets </span><span class="NormalTextRun SCXW7667757 BCX9">Aβ</span><span class="NormalTextRun SCXW7667757 BCX9"> soluble protofils and has shown statistical differences in mild AD or mild cognitive impairment. In its landmark phase III trial, lecanemab was shown to slow the progression of clinical decline, and a reduction in amyloid protein accumulation. The difference in mean CDR-SOB score improvement between the treatment and placebo groups was -0.45</span><span class="NormalTextRun SCXW7667757 BCX9">, of which the clinical significance could be argued. </span> <span class="NormalTextRun SCXW7667757 BCX9">Amyloid burden was also considerably reduced as well, but the true clinical consequence of this reduction remains to be seen. </span><span class="NormalTextRun SCXW7667757 BCX9">This</span><span class="NormalTextRun SCXW7667757 BCX9"> beneficial</span><span class="NormalTextRun SCXW7667757 BCX9"> impact on daily living is offset by rare but serious side effect</span><span class="NormalTextRun SCXW7667757 BCX9">s</span> <span class="NormalTextRun SCXW7667757 BCX9">including</span> <span class="NormalTextRun SCXW7667757 BCX9">amyloid-related imaging </span><span class="NormalTextRun SCXW7667757 BCX9">abnormalities</span> <span class="NormalTextRun SCXW7667757 BCX9">(ARIA) </span><span class="NormalTextRun SCXW7667757 BCX9">causing </span><span class="NormalTextRun SCXW7667757 BCX9">cerebral</span><span class="NormalTextRun SCXW7667757 BCX9"> edema </span><span class="NormalTextRun SCXW7667757 BCX9">(ARIA-E) </span><span class="NormalTextRun SCXW7667757 BCX9">or cere</span><span class="NormalTextRun SCXW7667757 BCX9">bral </span><span class="NormalTextRun SCXW7667757 BCX9">microhemorrhages or </span><span class="NormalTextRun SCXW7667757 BCX9">hemosiderin deposits</span><span class="NormalTextRun SCXW7667757 BCX9"> (ARIA-H).</span> <span class="NormalTextRun SCXW7667757 BCX9">Benefits of therapy must be considered against the risk of cerebral microhemorrhages and edema.</span> <span class="NormalTextRun SCXW7667757 BCX9">Affordability must also be taken into consideration. </span><span class="NormalTextRun SCXW7667757 BCX9">The current estimated yearly cost for twice </span><span class="NormalTextRun SCXW7667757 BCX9">monthly</span><span class="NormalTextRun SCXW7667757 BCX9"> lecanemab infusion is $26,500</span><span class="NormalTextRun SCXW7667757 BCX9">.</span><span class="NormalTextRun SCXW7667757 BCX9"> In addition to the significant cost challenges, the frequent infusions may pose concerns related to access.</span> <span class="NormalTextRun SCXW7667757 BCX9">Additional </span><span class="NormalTextRun SCXW7667757 BCX9">agents </span><span class="NormalTextRun SCXW7667757 BCX9">within this class </span><span class="NormalTextRun SCXW7667757 BCX9">are in the pipelines </span><span class="NormalTextRun SCXW7667757 BCX9">with possibly increased efficacy or decreased adverse events.</span><span class="NormalTextRun SCXW7667757 BCX9"> </span></span><span class="EOP SCXW7667757 BCX9" data-ccp-props="{"201341983":0,"335559739":0,"335559740":480}"> </span></p>Connie YoonCorey GroffOlivia Criss
Copyright (c) 2024 Connie Yoon, Corey Groff, Olivia Criss
https://creativecommons.org/licenses/by-nc/4.0
2024-03-182024-03-1815110.24926/iip.v15i1.5787Development and Evaluation of a Reliable Medication Management Self-Assessment Checklist
https://pubs.lib.umn.edu/index.php/innovations/article/view/5802
<p> An ability to effectively self-manage medications is the result of several factors influencing a person’s decision to take medications. The need for new approaches to medication self-management are evident in the persistent trends of ineffective and unfortunate medication use consequences, referred to as drug-related morbidity and mortality. Fortunately, pioneering initiatives have emerged to reshape our approach for developing a rational organizational paradigm so that patients can confidently self-manage medications.</p> <p> Favorable outcomes of studies pertaining to the delivery of comprehensive medication therapy management services within the practice of pharmaceutical care prompts the question, ‘Can patients and family members apply the 4-step pharmacotherapy workup process to better organize their decision-making and confidence in medication self-management?’ To answer this question an Effective Medication Self-Management Toolkit based on this 4-step process, and a Medication Management Self-efficacy Checklist, were created and evaluated for feasibility, acceptability, and internal consistency reliability.</p> <p> The first evaluation established the preliminary acceptability and feasibility of the toolkit using a convenience sample of 39 residents of independent living facilities in focus group sessions. All participants indicated they perceive that the 4-step process can help individuals successfully self-manage medications. At the conclusion of the focus group sessions, all 39 participants completed the 7-item post-session checklist. This paper presents the second evaluation to establish the internal consistency reliability of the toolkit’s Medication Management Self-efficacy Checklist using Cronbach’s alpha. There was good internal consistency of the self-efficacy checklist with a Cronbach’s alpha value of 0.82.</p> <p> This investigation of a novel approach for applying the 4-step pharmacotherapy assessment process by patients suggests that it is feasible and acceptable to use, and that the medication self-efficacy checklist provides a reliable and useful measure of a patient’s confidence in self-managing medications.</p>Brian IsettsKristine TalleyAnn Brearley
Copyright (c) 2024 Brian Isetts, Kristine Talley, Ann Brearley
https://creativecommons.org/licenses/by-nc/4.0
2024-03-182024-03-181511110.24926/iip.v15i1.5802